Abstract
We previously showed that antithymocyte globuline (ATG) given with TBI 200 cGy and fludarabine results in high rate of donor engraftment. Its influence on acute and chronic graft versus host disease (GVHD) and on graft versus tumor effect is less known. The reported rates of acute, grade II-IV GVHD after non-myeloablative stem cell transplantation (NST) have ranged from 20% to 58%. In the setting of NST, advanced recipient and/or donor ages increase the risk of GVHD. In addition, treatment of GVHD with high doses of corticosteroids is poorly tolerated in older adults.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
